Evaluation of Outcomes With Citalopram for Depression Using Measurement-Based Care in STAR*D: Implications for Clinical Practice

西酞普兰 萧条(经济学) 重性抑郁障碍 医学 评定量表 初级保健 重性抑郁发作 5-羟色胺再摄取抑制剂 精神科 内科学 临床实习 心理学 抗抑郁药 物理疗法 焦虑 家庭医学 认知 经济 宏观经济学 发展心理学
作者
Madhukar H. Trivedi,A. John Rush,Stephen R. Wisniewski,Andrew A. Nierenberg,Diane Warden,Louise Ritz,Grayson Norquist,Robert H. Howland,Barry D. Lebowitz,Patrick J. McGrath,Kathy Shores‐Wilson,Melanie M. Biggs,G.K. Balasubramani,Maurizio Fava,STAR*D Study Team
出处
期刊:American Journal of Psychiatry [American Psychiatric Association]
卷期号:163 (1): 28-40 被引量:3900
标识
DOI:10.1176/appi.ajp.163.1.28
摘要

OBJECTIVE: Selective serotonin reuptake inhibitors (SSRIs) are widely used to treat depression, but the rates, timing, and baseline predictors of remission in "real world" patients are not established. The authors' primary objectives in this study were to evaluate the effectiveness of citalopram, an SSRI, using measurement-based care in actual practice, and to identify predictors of symptom remission in outpatients with major depressive disorder. METHOD: This clinical study included outpatients with major depressive disorder who were treated in 23 psychiatric and 18 primary care "real world" settings. The patients received flexible doses of citalopram prescribed by clinicians for up to 14 weeks. The clinicians were assisted by a clinical research coordinator in the application of measurement-based care, which included the routine measurement of symptoms and side effects at each treatment visit and the use of a treatment manual that described when and how to modify medication doses based on these measures. Remission was defined as an exit score of or=50% in baseline QIDS-SR score. RESULTS: Nearly 80% of the 2,876 outpatients in the analyzed sample had chronic or recurrent major depression; most also had a number of comorbid general medical and psychiatric conditions. The mean exit citalopram dose was 41.8 mg/day. Remission rates were 28% (HAM-D) and 33% (QIDS-SR). The response rate was 47% (QIDS-SR). Patients in primary and psychiatric care settings did not differ in remission or response rates. A substantial portion of participants who achieved either response or remission at study exit did so at or after 8 weeks of treatment. Participants who were Caucasian, female, employed, or had higher levels of education or income had higher HAM-D remission rates; longer index episodes, more concurrent psychiatric disorders (especially anxiety disorders or drug abuse), more general medical disorders, and lower baseline function and quality of life were associated with lower HAM-D remission rates. CONCLUSIONS: The response and remission rates in this highly generalizable sample with substantial axis I and axis III comorbidity closely resemble those seen in 8-week efficacy trials. The systematic use of easily implemented measurement-based care procedures may have assisted in achieving these results.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
mymy发布了新的文献求助10
1秒前
1秒前
经十路以东的应助被侯侯采纳,获得10
2秒前
坚强灵竹完成签到,获得积分20
3秒前
nature大牛发布了新的文献求助10
4秒前
JamesPei的应助被桃汁采纳,获得10
4秒前
勒71发布了新的文献求助10
4秒前
5秒前
你好关注了科研通微信公众号
6秒前
7秒前
7秒前
研友_VZG7GZ的应助被勤劳的瑀采纳,获得10
7秒前
经十路以东的应助被冷艳的胜采纳,获得10
7秒前
所所的应助被健壮小馒头采纳,获得10
8秒前
8秒前
顾矜的应助被sjyu1985采纳,获得100
8秒前
9秒前
橘子汽水完成签到 ,获得积分10
9秒前
经十路以东的应助被yeeee采纳,获得10
9秒前
10秒前
lolimay完成签到,获得积分10
11秒前
11秒前
11秒前
12秒前
二三发布了新的文献求助10
12秒前
不会化学完成签到,获得积分10
12秒前
一木发布了新的文献求助10
14秒前
14秒前
酷波er的应助被美酶桑内采纳,获得10
15秒前
wanci的应助被凪凪采纳,获得10
15秒前
123william发布了新的文献求助10
15秒前
qiangqiangqiang完成签到 ,获得积分10
15秒前
16秒前
鹭江发布了新的文献求助10
17秒前
18秒前
焦一诺发布了新的文献求助10
18秒前
MMP发布了新的文献求助30
18秒前
万能图书馆的应助被Echo采纳,获得40
18秒前
Hong713完成签到,获得积分10
18秒前
脑洞疼的应助被Echo采纳,获得10
19秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Handbook of Sport Coaching Research 1000
Orthognathic Surgery - 2 Volume Set 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8193925
求助须知:如何正确求助?哪些是违规求助? 9579945
关于积分的说明 21868504
捐赠科研通 7793568
什么是DOI,文献DOI怎么找? 3437462
关于科研通互助平台的介绍 2560923
邀请新用户注册赠送积分活动 2484250